GRONINGEN, NETHERLANDS (30 September 2024) – VAR2 Pharmaceuticals ApS (‘VAR2 Pharma’) has received regulatory approval for their first-in-human Phase 0 clinical trial. In this study, the safety, tolerability, and biodistribution of two zirconium-89 labeled single-chain variable Fragments (scFvs) will be evaluated using PET/CT molecular imaging. The Danish company VAR2 Pharma is collaborating with TRACER, a […]
